Genmab ADR (NASDAQ: GMAB)’s stock price has soared by 0.53 in relation to previous closing price of 22.61. Nevertheless, the company has seen a gain of 1.29% in its stock price over the last five trading days. globenewswire.com reported 2025-02-25 that Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Is It Worth Investing in Genmab ADR (NASDAQ: GMAB) Right Now?
The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is 12.98x, which is above its average ratio. Moreover, the 36-month beta value for GMAB is 0.98. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for GMAB is 635.39M and currently, short sellers hold a 0.26% of that float. On February 28, 2025, GMAB’s average trading volume was 1.33M shares.
GMAB’s Market Performance
The stock of Genmab ADR (GMAB) has seen a 1.29% increase in the past week, with a 16.09% rise in the past month, and a 10.07% gain in the past quarter. The volatility ratio for the week is 1.36%, and the volatility levels for the past 30 days are at 2.10% for GMAB. The simple moving average for the last 20 days is 9.69% for GMAB’s stock, with a simple moving average of -6.41% for the last 200 days.
Analysts’ Opinion of GMAB
Many brokerage firms have already submitted their reports for GMAB stocks, with Leerink Partners repeating the rating for GMAB by listing it as a “Outperform.” The predicted price for GMAB in the upcoming period, according to Leerink Partners is $27 based on the research report published on February 13, 2025 of the current year 2025.
Morgan Stanley gave a rating of “Equal-Weight” to GMAB, setting the target price at $31 in the report published on September 04th of the previous year.
GMAB Trading at 9.12% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.70% of loss for the given period.
Volatility was left at 2.10%, however, over the last 30 days, the volatility rate increased by 1.36%, as shares surge +14.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.07% upper at present.
During the last 5 trading sessions, GMAB rose by +1.29%, which changed the moving average for the period of 200-days by -21.10% in comparison to the 20-day moving average, which settled at $20.72. In addition, Genmab ADR saw 8.91% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.95 for the gross margin
The net margin for Genmab ADR stands at 0.36. The total capital return value is set at 0.17. Equity return is now at value 23.16, with 19.54 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 7.55. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 68.4.
Currently, EBITDA for the company is 7.39 billion with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 4.36. The receivables turnover for the company is 3.27for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.25.
Conclusion
To wrap up, the performance of Genmab ADR (GMAB) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
